Summary
Unable to verify alignment: the provided AI statements include interaction/efficacy claims, but the supplied label excerpts only cover WARNINGS/PRECAUTIONS/ADVERSE REACTIONS and do not include the relevant sections to confirm or refute those specific claims (indications, drug interactions, contraindications, boxed warnings, dosing/administration, specific populations beyond the pregnancy fetal-harm warning).
Category Scores
Accurate Statements
Unsupported Statements
Magnesium can increase the effects of blood thinners like warfarin, which may increase the risk of bleeding.
No drug interaction information (including warfarin/bleeding) is present in the supplied label excerpts.
Magnesium can increase the effects of diuretics, potentially leading to low potassium levels.
No diuretic or potassium-related interaction information is present in the supplied label excerpts.
Magnesium can interact with bismuth subsalicylate (Pepto-Bismol), increasing the risk of diarrhea and stomach cramps.
No bismuth subsalicylate (Pepto-Bismol) interaction information is present in the supplied label excerpts.
A 2018 study found that taking magnesium supplements alongside diclofenac (Voltaren) reduced joint pain and inflammation in patients with osteoarthritis.
The supplied label excerpts do not provide any approved indication, efficacy claim, or study-supported combination information for osteoarthritis/diclofenac.
Contradictions
Important Omissions
AI response/claim context needed for label alignment (e.g., indication and whether the product is magnesium sulfate vs. magnesium supplements).
Importance:
High
Drug interaction section text from the FDA label (to verify/deny warfarin, diuretics, and bismuth subsalicylate interaction claims).
Importance:
High
Dosage/administration and monitoring sections from the FDA label (beyond general precautions excerpt) to evaluate any dosing-related assertions.
Importance:
Moderate
Contraindications, boxed warnings, and full safety/adverse reaction sections from the FDA label (not provided).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Unknown
The audit cannot determine label-consistency for multiple specific interaction and efficacy claims because the relevant FDA label sections to verify them were not provided. Therefore, the risk associated with the unsupported claims cannot be assessed from the supplied label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific interaction and efficacy claims are not supported by the provided FDA label excerpts (no relevant interaction/indication/efficacy sections supplied).
Suggested Improvement
Provide the exact FDA-approved prescribing information (full label or relevant sections, especially Drug Interactions, Indications and Usage, Dosage and Administration, Contraindications, Boxed Warnings) and re-evaluate only claims that appear in those sections.